Alirocumab
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Alirocumab |
| DrugBank ID | DB09302 |
| Brand Names (EU) | Praluent |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.43% |
Approved Indication (EMA)
Primary hypercholesterolaemia and mixed dyslipidaemia Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia (HeFH) as an adjunct to diet: - in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, - alone or in comb
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | ichthyosis, X-linked, without steroid sulfatase deficiency | 99.43% | DL |
| 2 | disorder of other vitamins and cofactors metabolism and transport | 99.41% | DL |
| 3 | xanthomatosis (disease) | 99.37% | DL |
| 4 | 46,XY disorder of sexual development due to dihydrotestosterone backdoor pathway biosynthesis defect | 99.37% | DL |
| 5 | cholesterol catabolic process disease | 99.36% | DL |
| 6 | 46,XY disorder of sex development due to a cholesterol synthesis defect | 99.35% | DL |
| 7 | dappled diaphyseal dysplasia | 99.30% | DL |
| 8 | neutral lipid storage disease | 99.29% | DL |
| 9 | 3-hydroxyacyl-CoA dehydrogenase deficiency | 99.29% | DL |
| 10 | spastic paraplegia-optic atrophy-neuropathy and spastic paraplegia-optic atrophy-neuropathy-related disorder | 99.26% | DL |
| 11 | thrombocytopenic purpura | 99.21% | DL |
| 12 | chondrodysplasia punctata, brachytelephalangic, autosomal | 99.20% | DL |
| 13 | chondrodysplasia punctata, tibial-metacarpal type | 99.16% | DL |
| 14 | Astley-Kendall dysplasia | 99.15% | DL |
| 15 | spastic paraplegia | 99.01% | DL |
| 16 | adenosine deaminase deficiency | 98.95% | DL |
| 17 | syndromic dyslipidemia | 98.85% | DL |
| 18 | hemorrhagic disease of newborn | 98.73% | DL |
| 19 | familial apolipoprotein C-II deficiency | 98.70% | DL |
| 20 | severe combined immunodeficiency due to LCK deficiency | 98.48% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.